Abstract
BACKGROUND: Skin fibrosis is a significant medical problem with limited available treatment modalities. The key cellular characteristics include increased fibroblast proliferation, collagen production, and transforming growth factor-beta (TGF-B)/SMAD pathway signaling. The authors have previously shown that high-fluence light-emitting diode red light (HF-LED-RL) decreases cellular proliferation and collagen production. OBJECTIVE: Herein, the authors investigate the ability of HF-LED-RL to modulate the TGF-B/SMAD pathway. MATERIALS AND METHODS: Normal human dermal fibroblasts were cultured and irradiated with a commercially available hand-held LED array. After irradiation, cell lysates were collected and levels of pSMAD2, TGF-Beta 1, and TGF-Beta I receptor were measured using Western blot. RESULTS: High-fluence light-emitting diode red light decreased TGF-Beta 1 ligand (TGF-B1) levels after irradiation. 320 J/cm HF-LED-RL resulted in 59% TGF-B1 and 640 J/cm HF-LED-RL resulted in 54% TGF-B1, relative to controls. 640 J/cm HF-LED-RL resulted in 62% pSMAD2 0 hours after irradiation, 65% pSMAD2 2 hours after irradiation, and 95% 4 hours after irradiation, compared with matched controls. High-fluence light-emitting diode red light resulted in no significant difference in transforming growth factor-beta receptor I levels compared with matched controls. CONCLUSION: Skin fibrosis is a significant medical problem with limited available treatment modalities. Light-emitting diode-generated red light is a safe, economic, and noninvasive modality that has a body of in vitro evidence supporting the reduction of key cellular characteristics associated with skin fibrosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1317-1322 |
| Number of pages | 6 |
| Journal | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] |
| Volume | 44 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Dermatology
Cite this
High-Fluence Light-Emitting Diode-Generated Red Light Modulates the Transforming Growth Factor-Beta Pathway in Human Skin Fibroblasts. / Mamalis, Andrew; Jagdeo, Jared.
In: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], Vol. 44, No. 10, 01.10.2018, p. 1317-1322.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-Fluence Light-Emitting Diode-Generated Red Light Modulates the Transforming Growth Factor-Beta Pathway in Human Skin Fibroblasts
AU - Mamalis, Andrew
AU - Jagdeo, Jared
PY - 2018/10/1
Y1 - 2018/10/1
N2 - BACKGROUND: Skin fibrosis is a significant medical problem with limited available treatment modalities. The key cellular characteristics include increased fibroblast proliferation, collagen production, and transforming growth factor-beta (TGF-B)/SMAD pathway signaling. The authors have previously shown that high-fluence light-emitting diode red light (HF-LED-RL) decreases cellular proliferation and collagen production. OBJECTIVE: Herein, the authors investigate the ability of HF-LED-RL to modulate the TGF-B/SMAD pathway. MATERIALS AND METHODS: Normal human dermal fibroblasts were cultured and irradiated with a commercially available hand-held LED array. After irradiation, cell lysates were collected and levels of pSMAD2, TGF-Beta 1, and TGF-Beta I receptor were measured using Western blot. RESULTS: High-fluence light-emitting diode red light decreased TGF-Beta 1 ligand (TGF-B1) levels after irradiation. 320 J/cm HF-LED-RL resulted in 59% TGF-B1 and 640 J/cm HF-LED-RL resulted in 54% TGF-B1, relative to controls. 640 J/cm HF-LED-RL resulted in 62% pSMAD2 0 hours after irradiation, 65% pSMAD2 2 hours after irradiation, and 95% 4 hours after irradiation, compared with matched controls. High-fluence light-emitting diode red light resulted in no significant difference in transforming growth factor-beta receptor I levels compared with matched controls. CONCLUSION: Skin fibrosis is a significant medical problem with limited available treatment modalities. Light-emitting diode-generated red light is a safe, economic, and noninvasive modality that has a body of in vitro evidence supporting the reduction of key cellular characteristics associated with skin fibrosis.
AB - BACKGROUND: Skin fibrosis is a significant medical problem with limited available treatment modalities. The key cellular characteristics include increased fibroblast proliferation, collagen production, and transforming growth factor-beta (TGF-B)/SMAD pathway signaling. The authors have previously shown that high-fluence light-emitting diode red light (HF-LED-RL) decreases cellular proliferation and collagen production. OBJECTIVE: Herein, the authors investigate the ability of HF-LED-RL to modulate the TGF-B/SMAD pathway. MATERIALS AND METHODS: Normal human dermal fibroblasts were cultured and irradiated with a commercially available hand-held LED array. After irradiation, cell lysates were collected and levels of pSMAD2, TGF-Beta 1, and TGF-Beta I receptor were measured using Western blot. RESULTS: High-fluence light-emitting diode red light decreased TGF-Beta 1 ligand (TGF-B1) levels after irradiation. 320 J/cm HF-LED-RL resulted in 59% TGF-B1 and 640 J/cm HF-LED-RL resulted in 54% TGF-B1, relative to controls. 640 J/cm HF-LED-RL resulted in 62% pSMAD2 0 hours after irradiation, 65% pSMAD2 2 hours after irradiation, and 95% 4 hours after irradiation, compared with matched controls. High-fluence light-emitting diode red light resulted in no significant difference in transforming growth factor-beta receptor I levels compared with matched controls. CONCLUSION: Skin fibrosis is a significant medical problem with limited available treatment modalities. Light-emitting diode-generated red light is a safe, economic, and noninvasive modality that has a body of in vitro evidence supporting the reduction of key cellular characteristics associated with skin fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85057072165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057072165&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000001549
DO - 10.1097/DSS.0000000000001549
M3 - Article
C2 - 29846344
AN - SCOPUS:85057072165
VL - 44
SP - 1317
EP - 1322
JO - Dermatologic Surgery
JF - Dermatologic Surgery
SN - 1076-0512
IS - 10
ER -